Toronto, Ontario – August 1, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fourth patient was treated, utilizing the Therapeutic Dose (0.70 mg/cm2) on July 20, 2017 for Non-Muscle Invasive Bladder (“NMIBC”) cancer using its novel Photo Dynamic Therapy (“PDT”) technology. These patients come from a population that has failed standard of care and have remained drug resistant after the standard first line Bacillus Calmette Guérin (“BCG”) course of treatments. The Phase Ib NMIBC clinical study (“Study”) is entitled “A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients with Non-Muscle Invasive Bladder Cancer at High Risk of Progression Who are Refractory to Therapy with Bacillus Calmette-Guérin (“BCG”) and Who are Medically Unfit for or Refuse a … Read More

Toronto, Ontario – July 25, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that at the Maximum Recommended Starting Dose (“MRSD”) (0.35 mg/cm2) of its lead compound, TLD-1433, at the ninety (90) day cystoscopy analysis, the Company has achieved the exploratory endpoint of efficacy in patients inflicted with Non-Muscle Invasive Bladder Cancer (“NMIBC”). These three patients come from a population that has failed standard of care and have remained drug resistant after the standard first line Bacillus Calmette Guérin (“BCG”) course of treatments. The exploratory efficacy endpoint is being reported at ninety (90) days, in the first 3 patients treated, in the first part of a Phase Ib clinical study (“Study“). The Study is entitled “A Phase … Read More

Toronto, Ontario – July 5, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that release of two pre-recorded videos aired at the completion of the Company’s Annual and Special Meeting, held at the Company’s corporate office on June 30, 2017. The pre-recorded videos feature Dr. Michael Jewett, uro-oncologist of Princess Margaret Cancer Centre, University Health Network (“UHN”) and Dr. Girish Kulkarni, uro-oncologist, UHN. Youtube videos and links to both: Dr. Jewett Link: https://youtu.be/0awLP-R5gRA   Dr. Kulkarni Link: https://youtu.be/3P_Pvq1kzVc   Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase is delighted to be associated with both Dr. Jewett and Dr. Kulkarni and their combined expertise in the field of uro-oncology. Their experience and guidance is key … Read More

Toronto, Ontario – June 30, 2017   Further to its press releases dated November 1, 2016, May 1, 2017 and May 30, 2017, Theralase Technologies Inc. (“Theralase” or the “Corporation”) (TSXV:TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds to destroy cancer, wishes to provide clarification with respect to certain forward-looking statements included in a number of historical interviews conducted with management representatives from 2010 to 2016 and in certain corporate presentations prepared by the Corporation between 2013 and 2016. Such forward-looking statements included statements with respect to projected sales of up to $10 million per year for upcoming fiscal years, as well as certain other long term projections. Such statements may constitute forward-looking information within the meaning of National Instrument 51-102 – Continuous Disclosure and certain of those projections were subject to various underlying … Read More

Toronto, Ontario – June 29, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that the Theralase therapeutic laser technology has been proven effective in the treatment of arthritis in recently published animal research. The research was published online May 30, 2017 in Lasers in Medical Science, entitled, “Low-intensity laser therapy efficacy evaluation in FVB mice subjected to acute and chronic arthritis”, authored by Joào Paulo Mardegan Issa, Bianca Ferreira Trawitzki, Edilson Ervolino, Ana Paula Macedo and Lothar Lilge. An abstract to the publication is available here: https://link.springer.com/article/10.1007/s10103-017-2235-5 Rheumatoid arthritis, a chronic inflammatory disorder, has a high prevalence in the population and while therapy is available, it often requires injection of drugs causing discomfort to patients. This study … Read More

Toronto, Ontario – June 26, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that the U.S. Patent and Trademark Office (“USPTO”) has issued a second patent on its lead anti-cancer compound technology licensed by Theralase from Dr. Sherri McFarland. The USPTO granted U.S. Patent Number 9,676,806 B2 entitled, “Metal-Based Thiophene Photodynamic Compounds and Their Use”, which issued on June 13, 2017, as a continuation of U.S. Patent No. 9,345,769. The patent deals with the composition of tunable metal-based thiophene PDCs used as therapeutic agents and as in-vivo diagnostic agents for treating or preventing diseases that involve hyperproliferating cell etiology, including: cancer and diseases associated with hyperproliferating cells. The compositions are also useful for treating infectious diseases … Read More

Toronto, Ontario – June 15, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research on phosphorescent photosensitizers was recently presented on June 12th, at the 16th International Photodynamic Association (“IPA”) World Congress held from June 8th to 13th, 2017 in Coimbra, Portugal. The IPA was founded in 1986 and its membership consists of some of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The IPA promotes the study of diagnosis and clinical treatment using light and Photo Sensitizers (“PSs”), and disseminates this knowledge to IPA members, the medical community and the general public. The IPA World Congress is held every two years and is … Read More

Toronto, Ontario – June 14, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research on X-ray activation of PDCs was recently presented on June 12th, at the 16th International Photodynamic Association (“IPA”) World Congress held from June 8th to 13th, 2017 in Coimbra, Portugal. The IPA was founded in 1986 and its membership consists of some of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The IPA promotes the study of diagnosis and clinical treatment using light and Photo Sensitizers (“PSs”), and disseminates this knowledge to IPA members, the medical community and the general public. The IPA World Congress is held every two … Read More

Toronto, Ontario – June 13, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research on dosimetry planning and Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study data (“Study”) was recently presented on June 9th, at the 16th International Photodynamic Association (“IPA”) World Congress held from June 8th to 13th, 2017 in Coimbra, Portugal. The IPA was founded in 1986 and its membership consists of some of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The IPA promotes the study of diagnosis and clinical treatment using light and Photo Sensitizers (“PSs”), and disseminates this knowledge to IPA members, the medical community and the … Read More

Toronto, Ontario – June 2, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSX-V: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has qualified to trade on the OTCQX® Best Market in the United States. Effective immediately, Theralase has been upgraded to commence trading on the OTCQX market from the Pink® market under the symbol “TLTFF”. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. “Trading on the OTCQX will allow Theralase to build visibility and provide a more transparent market for U.S. investors,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. “We are pleased to welcome Theralase to OTCQX and look forward to supporting the company and its shareholders in the public … Read More